Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV and decompensated cirrhosis.

Gilead said Epclusa is the first single-tablet, pan-genotypic, once-daily treatment approved in China to treat HCV. It is a fixed-dose combination of Sovaldi sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor; and velpatasvir (GS-5816), a pan-genotypic HCV NS5A protein inhibitor. FDA and EMA approved Epclusa in 2016...